ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109,665 | -42.7% | 20,122 | -29.5% | 0.00% | – |
| Q2 2023 | $191,430 | +2.1% | 28,529 | +34.4% | 0.00% | – |
| Q1 2023 | $187,479 | +16.2% | 21,232 | +0.5% | 0.00% | – |
| Q4 2022 | $161,403 | +17.8% | 21,126 | +9.8% | 0.00% | – |
| Q3 2022 | $137,000 | -11.6% | 19,239 | +0.5% | 0.00% | – |
| Q2 2022 | $155,000 | -42.2% | 19,145 | -0.7% | 0.00% | – |
| Q1 2022 | $268,000 | -50.1% | 19,275 | +0.7% | 0.00% | -100.0% |
| Q4 2021 | $537,000 | -18.5% | 19,144 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $659,000 | -16.8% | 19,380 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $792,000 | -4.9% | 19,380 | -6.3% | 0.00% | -50.0% |
| Q1 2021 | $833,000 | -39.3% | 20,687 | -10.9% | 0.00% | -33.3% |
| Q4 2020 | $1,372,000 | -12.1% | 23,210 | -27.7% | 0.00% | -25.0% |
| Q3 2020 | $1,561,000 | +2.6% | 32,107 | +2.1% | 0.00% | 0.0% |
| Q2 2020 | $1,522,000 | +75.3% | 31,450 | +0.6% | 0.00% | +33.3% |
| Q1 2020 | $868,000 | – | 31,250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |